Truist raised the firm’s price target on Lantheus to $82 from $80 and keeps a Buy rating on the shares. The company’s stock does not reflect the appropriate value for Pylarify and the “core” business that are worth at least $78 per share, the analyst tells investors in a research note. Lantheus out-year EPS power also “remains underappreciated”, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LNTH:
- Lantheus to Present at the TD Cowen 44th Annual Health Care Conference
- Lantheus management to meet with B. Riley
- Lantheus price target raised to $128 from $114 at JonesResearch
- Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results
- Lantheus sees Q1 adjusted EPS $1.50-$1.54, consensus $1.51
